Clinical Trial Update: Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating enasidenib as maintenance therapy after allogeneic stem cell transplantation in patients with IDH2-mutated acute myeloid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Enasidenib (enasidenib)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING